The involvement of GLUT1 and CAIX in the early stages of carcinogenesis, that is, in the metabolic “shift,” points to their potential application in distinguishing between benign and malignant lesions rather than in prediction of prognosis in endometrial cancer patients. The gene discussed is CA9; the disease is endometrial cancer.